Shares of AstraZeneca plc (LON:AZN) have received an average rating of “Hold” from the nineteen analysts that are currently covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation and ten have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is GBX 6,592.86 ($86.15).
A number of brokerages have recently weighed in on AZN. Liberum Capital restated a “hold” rating on shares of AstraZeneca in a research report on Friday, March 29th. UBS Group restated a “sell” rating on shares of AstraZeneca in a research report on Thursday, June 20th. Deutsche Bank set a GBX 6,800 ($88.85) price target on shares of AstraZeneca and gave the company a “buy” rating in a report on Monday. Jefferies Financial Group reaffirmed a “hold” rating on shares of AstraZeneca in a report on Thursday, March 14th. Finally, Goldman Sachs Group reaffirmed a “sell” rating on shares of AstraZeneca in a report on Monday, March 18th.
In other news, insider Marc Dunoyer acquired 8,500 shares of the firm’s stock in a transaction on Tuesday, May 7th. The stock was acquired at an average price of GBX 5,800 ($75.79) per share, with a total value of £493,000 ($644,191.82). Also, insider Philip A. J. Broadley acquired 520 shares of the firm’s stock in a transaction on Tuesday, April 30th. The stock was purchased at an average cost of GBX 5,738 ($74.98) per share, with a total value of £29,837.60 ($38,988.11).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Story: Average Daily Trade Volume – What It Means In Stock Trading
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.